Investigation Report on China Repaglinide Market, 2010-2019

Publisher Name :
Date: 02-Jul-2015
No. of pages: 30

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.

There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million.??

Entering China after 2000, insulin secretagogues agent is mainly used for the treatment of type 2 diabetes. Currently, there are only 3 kinds available in the Chinese market, namely, nateglinide, repaglinide and mitiglinide. They share the same mechanism of action, that is to say, they lower blood glucose by stimulating the release of insulin from the beta cells. Compared with sulfonylurea, insulin secretagogues agent reports shorter duration of glucoselowering action and lower rate of hypoglycemia.

As an insulin secretagogues agent structured different from sulfonylurea, repaglinide is used to control postprandial hyperglycemia. Developed by Novo Nordisk A/S and BoehringerIngelheim together, it entered the United States in Apr. 1998.

As the first new prandial glucose regulator, repaglinide belongs to the class of benzoic acid derivative. Containing a chiral carbon atom, it has stereoselective activity and can be absorbed well on an empty stomach or not. As repaglinide is expelled from the body with bile after being metabolized by CYP3A4 enzyme system in the liver and only 6% of it is excreted through kidney, it is more suitable for patients with kidney disorders. Hence its advantage in the clinic. In 2000, repaglinide of Novo Nordisk A/S came to be sold in China under the name of Novonorm. According to CRI's market survey, it has few rivals and takes up a market share of about 89% for sales value while its main competitor Hanson Pharmaceutical only occupies less than 11% of the market. The sales value of repaglinide in sample hospitals was about CNY 125 million in 2014 and CAGR during the period of 20052014 reached about 22%.

The market size of repaglinide is expected to keep growing in the next few years in China.

Readers can get at least the following information through this report:


  • market size of repaglinide in China

  • major manufacturers of repaglinide for Chinese market and their market share

  • retail price of repaglinide in Chinese market

  • market outlook of repaglinide in China


The author suggests the following groups of people purchase this report:


  • manufacturers of antidiabetic drugs

  • investors/ research institutions interested in Chinese medicine market

  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Investigation Report on China Repaglinide Market, 2010-2019

Table of Contents

1 Related Concepts of Repaglinide
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Repaglinide in China
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Repaglinide in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Repaglinide in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Repaglinide in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Repaglinide in Chinese Hospitals in 2014
6.1 Novo Nordisk A/S (Denmark)
6.2 Hanson Pharmaceutical
6.3 Tianjin Kangrui Pharmaceutical Co., Ltd
6.4 Beijing Wansheng Pharmaceutical Co., Ltd

7 Major Manufacturers of Repaglinide in Chinese Market, 2010-2014
7.1 Novo Nordisk A/S (Denmark)
7.2 Hanson Pharmaceutical
7.3 Tianjin Kangrui Pharmaceutical Co., Ltd
7.4 Beijing Wansheng Pharmaceutical Co., Ltd

8 Market Outlook of Repaglinide in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

List of Charts

Chart Patent Registration Information of Repaglinide in China
Chart Approval Status of Repaglinide in China
Chart Sales Status of Repaglinide in China, 2010-2014
Chart Sales Value of Repaglinide in China, 2010-2014
Chart Sales Value of Repaglinide by Regions in China, 2010-2014
Chart Sales Value of Repaglinide Tablets in China, 2010-2014
Chart Sales Value of Repaglinide Capsules in China, 2010-2014
Chart Market Share of Major Manufacturers of Repaglinide for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Repaglinide Made by Novo Nordisk A/S, 2010-2014
Chart Sales Value and Market Share of Repaglinide Made by Hanson Pharmaceutical, 2010-2014
Chart Sales Value and Market Share of Repaglinide Made by Tianjin Kangrui Pharmaceutical Co., Ltd, 2010-2014
Chart Price of Repaglinide Made by Novo Nordisk A/S in Some Chinese Cities in 2014
Chart Price of Repaglinide Made by Hanson Pharmaceutical in Some Chinese Cities in 2014
Chart Price of Repaglinide Made by Tianjin Kangrui Pharmaceutical Co., Ltd in Some Chinese Cities in 2014

  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Asia-Pacific Insulin Glargine Market Report 2017
    Published: 10-Apr-2017        Price: US 4000 Onwards        Pages: 105
    In this report, the Asia-Pacific Insulin Glargine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (M ml), revenue (Million USD), market share and growth rate of Insulin Glargine for these regions, from 2012 to 2022 (forecast), including - China - Japan - South Korea - T......
  • Insulin Companies in China
    Published: 05-Apr-2017        Price: US 1800 Onwards        Pages: 65
    This study focuses on China's Insulin industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods ......
  • Insulin Markets in China
    Published: 05-Apr-2017        Price: US 4000 Onwards        Pages: 220
    China's demand for Insulin has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry str......
  • Insulin Industry Forecasts - China Focus
    Published: 05-Apr-2017        Price: US 1800 Onwards        Pages: 109
    This study focuses on China's Insulin industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. The Chin......
  • EMEA (Europe, Middle East and Africa) Medium Voltage Cables & Accessories Market Report 2017
    Published: 04-Apr-2017        Price: US 4000 Onwards        Pages: 113
    In this report, the EMEA Medium Voltage Cables & Accessories market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Medium Voltage Cables & Accessories for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France......
  • EMEA (Europe, Middle East and Africa) Metformin Hydrochloride Market Report 2017
    Published: 04-Apr-2017        Price: US 4000 Onwards        Pages: 119
    In this report, the EMEA Metformin Hydrochloride market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (MT), revenue (Million USD), market share and growth rate of Metformin Hydrochloride for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Italy and Benel......
  • EMEA (Europe, Middle East and Africa) Insulin Glargine Market Report 2017
    Published: 30-Mar-2017        Price: US 4000 Onwards        Pages: 100
    In this report, the EMEA Insulin Glargine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (M ml), revenue (Million USD), market share and growth rate of Insulin Glargine for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Italy and Benelux; -......
  • Diabetes Drugs Markets in China
    Published: 18-Mar-2017        Price: US 4000 Onwards        Pages: 214
    China's demand for Diabetes Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry......
  • Diabetes Drugs Industry Forecasts - China Focus
    Published: 18-Mar-2017        Price: US 1800 Onwards        Pages: 92
    This study focuses on China's Diabetes Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. The ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs